NCT05309135View on ClinicalTrials.gov

A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 24, 2022

Primary Completion Date

March 9, 2023

Study Completion Date

March 9, 2023

Conditions
Corneal Edema
Interventions
DRUG

HCEC-1

HCEC-1 = human cultured corneal endothelial cells and Rho kinase Y-27632 inhibitor

Trial Locations (1)

Unknown

Site, San Salvador

Sponsors

Lead Sponsor

Aurion Biotech
All Listed Sponsors
lead

Aurion Biotech

INDUSTRY